About this Journal Submit a Manuscript Table of Contents
Obstetrics and Gynecology International
Volume 2013 (2013), Article ID 708023, 11 pages
http://dx.doi.org/10.1155/2013/708023
Review Article

The Evidence Regarding Maintenance Tocolysis

1Perinatal Services, Division of Southwest Contemporary Women's Care, Southwest Perinatal Services, 16611 S. 40th Street, Phoenix, AZ 85048, USA
2Department of OB/GYN, University of Mississippi Medical Center, Jackson, MS 39216, USA

Received 28 November 2012; Revised 24 January 2013; Accepted 30 January 2013

Academic Editor: Everett Magann

Copyright © 2013 John P. Elliott and John C. Morrison. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. E. Hamilton, J. A. Martin, and S. J. Ventura, “Births: preliminary data for 2009,” National Vital Statistics Reports, vol. 59, no. 3, pp. 1–10.
  2. T. J. Mathews and M. F. MacDorman, “Infant mortality statistics from the 2006 period linked birth/infant death data set,” National Vital Statistics Reports, vol. 58, no. 17, pp. 1–31, 2010. View at Scopus
  3. R. L. Goldenberg, J. F. Culhane, J. D. Iams, and R. Romero, “Epidemiology and causes of preterm birth,” The Lancet, vol. 371, no. 9606, pp. 75–84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. P. Elliott, D. F. Lewis, J. C. Morrison, and T. J. Garite, “In defense of magnesium sulfate,” Obstetrics and Gynecology, vol. 113, no. 6, pp. 1341–1348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. O. A. Rust, J. A. Bofill, R. M. Arriola, M. E. Andrew, and J. C. Morrison, “The clinical efficacy of oral tocolytic therapy,” The American Journal of Obstetrics and Gynecology, vol. 175, no. 4 I, pp. 838–842, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. J. G. Thornton, “Maintenance tocolysis,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 112, supplement 1, pp. 118–121, 2005. View at Scopus
  7. J. M. Dodd, C. A. Crowther, M. R. Dare, and P. Middleton, “Oral betamimetics for maintenance therapy after threatened preterm labour,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD003927, 2006. View at Scopus
  8. D. J. Lyell, K. M. Pullen, J. Mannan et al., “Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial,” Obstetrics and Gynecology, vol. 112, no. 6, pp. 1221–1226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. G. J. Valenzuela, L. Sanchez-Ramos, R. Romero et al., “Maintenance treatment of preterm labor with the oxytocin antagonist atosiban,” The American Journal of Obstetrics and Gynecology, vol. 182, no. 5, pp. 1184–1190, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. J. C. Morrison, J. P. Elliott, and S. Jones, “Uterine contraction monitoring, maintenance tocolysis and preterm birth,” in Preterm Birth: Mother and Child, pp. 201–212, InTech, Rijeka, Croatia, 2011.
  11. F. Lam, W. K. Graves, and W. G. Peacock, “The impact of portable tocodynamometry and subcutaneous Terbutaline pump therapy on preterm birth in a private obstetrical practice,” in Proceedings of the ACOG Districts 8th and 9th Meeting, Las Vegas, Nev, USA, September 1987.
  12. F. Lam, P. Gill, M. Smith, J. L. Kitzmiller, and M. Katz, “Use of the subcutaneous terbutaline pump for long-term tocolysis,” Obstetrics and Gynecology, vol. 72, no. 5, pp. 810–813, 1988.
  13. F. Lam, P. J. Gill, and M. Smith, “Comparison of portable subcutaneous terbutaline pump and oral terbutaline treatment for long-term tocolysis: a randomized clinical trial,” in Proceedings of the 8th Annual Meeting Society of Perinatal Obstetricians, abstract 400, Las Vegas, Nev, USA, February 1988.
  14. J. Gianopoulos, N. Carlson, and B. Schumachen, “SQ terbutaline pump for premature labor,” The American Journal of Obstetrics and Gynecology, vol. 164, article 426, 1991.
  15. P. Jones, J. S. Greenspan, C. J. Bochner, et al., “Continuous subcutaneous terbutaline infusion for the prevention of recurrent preterm labor,” American Journal of Obstetrics and Gynecology, vol. 164, article 426, 1991.
  16. J. R. Fischer and B. L. Kaatz, “Continuous subcutaneous infusion of terbutaline for suppression of preterm labor,” Clinical Pharmacology, vol. 10, no. 4, pp. 292–296, 1991.
  17. M. McGettigan, V. Bhutani, and A. Rathbone, “Prenatal b-mimetic exposure of the newborn: maternal oral versus continuous infusion therapy,” Pediatric Research, vol. 30, article 62A, 1991.
  18. R. N. Wolfsen and S. K. Winn, “Prolongation of twin pregnancy with magnesium sulphate/subcutaneous terbutaline pump therapy in the face of advanced cervical dilatation and effacement,” American Journal of Obstetrics and Gynecology, vol. 166, no. 1, p. 366, 1992.
  19. J. R. Allbert, C. A. Wise, C. H. Lou, K. S. Gookin, M. A. Parmenter, and J. C. Morrison, “Subcutaneous tocolytic therapy for patients at very high risk for preterm birth,” Journal of Perinatology, vol. 12, no. 1, pp. 28–31, 1992.
  20. C. Lindenbaum, J. Ludmir, F. B. Teplick, A. W. Cohen, and P. Samuels, “Maternal glucose intolerance and the subcutaneous terbutaline pump,” American Journal of Obstetrics and Gynecology, vol. 166, no. 3, pp. 925–928, 1992.
  21. K. J. Moise Jr., D. J. Sala, R. K. Zurawin, L. E. Cano, D. E. Hesketh, and R. J. Carpenter Jr., “Continuous subcutaneous terbutaline pump therapy for premature labor, safety and efficacy,” Southern Medical Journal, vol. 85, no. 3, pp. 255–259, 1992. View at Publisher · View at Google Scholar
  22. P. Weinbaum and M. Olson, “The effect of subcutaneous infusion on uterine activity in patients at risk for preterm delivery,” American Journal of Obstetrics and Gynecology, vol. 166, article 362, 1993.
  23. J. P. Elliott and T. G. Radin, “Quadruplet pregnancy: contemporary management and outcome,” Obstetrics and Gynecology, vol. 80, no. 3, part 1, pp. 421–424, 1992.
  24. R. T. Adkins, J. E. van Hooydonk, P. L. Bressman et al., “Prevention of preterm birth: early detection and aggressive treatment with terbutaline,” Southern Medical Journal, vol. 86, no. 2, pp. 157–164, 1993. View at Publisher · View at Google Scholar
  25. A. C. Regenstein, J. Belluomini, and M. Katz, “Terbutaline tocolysis and glucose intolerance,” Obstetrics and Gynecology, vol. 81, no. 5, part 1, pp. 739–741, 1993.
  26. J. R. Allbert, C. Johnson, W. E. Roberts, R. W. Martin, K. S. Gookin, and J. C. Morrison, “Tocolysis for recurrent preterm labor using a continuous subcutaneous infusion pump,” Journal of Reproductive Medicine, vol. 39, no. 8, pp. 614–618, 1994.
  27. K. G. Perry, J. C. Morrison, O. A. Rust, C. A. Sullivan, R. W. Martin, and R. W. Naef III, “Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion,” The American Journal of Obstetrics and Gynecology, vol. 173, no. 4, pp. 1273–1277, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. J. P. Elliott, M. J. Flynn, E. L. Kaemmerer, and T. G. Radin, “Terbutaline pump tocolysis in high order multiple gestation,” Journal of Reproductive Medicine, vol. 42, no. 11, pp. 687–694, 1997.
  29. K. D. Wenstrom, C. P. Weiner, D. Merrill, and J. Niebyl, “A placebo-controlled randomized trial of the terbutaline pump for prevention of preterm delivery,” The American Journal of Perinatology, vol. 14, no. 2, pp. 87–91, 1997. View at Scopus
  30. D. A. Guinn, A. R. Goepfert, J. Owen, K. D. Wenstrom, and J. C. Hauth, “Terbutaline pump maintenance therapy for prevention of preterm delivery: a double-blind trial,” The American Journal of Obstetrics and Gynecology, vol. 179, no. 4, pp. 874–878, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Lam, N. K. Bergauer, G. J. Stanziano, et al., “Pregnancy prolongation and route of tocolytic administration in patients with singleton gestation,” American Journal of Obstetrics and Gynecology, vol. 178, article 180, 1998.
  32. M. Berkus, O. Langer, and K. Kigby, “Effect of terbutaline pump on maternal glucose metabolism,” American Journal of Obstetrics and Gynecology, vol. 180, no. 1, article S41, 1999.
  33. S. Hammersley, T. Pinckert, and K. Gorman, “The use of continuous subcutaneous terbutaline in a private maternal-fetal medicine practice,” Obstetrics and Gynecology, vol. 93, pp. 67–68, 1999.
  34. F. Lam, N. K. Bergauer, S. K. Coleman, G. J. Stanziano, and D. Jacques, “A comparison of gestational days gained with oral terbutaline versus continuous subcutaneous terbutaline in women with twin gestations,” Journal of Perinatology, vol. 20, no. 7, pp. 408–413, 2000.
  35. S. Ambrose, D. J. Rhea, N. B. Istwan, A. Collins, and G. Stanziano, “Clinical and economic outcomes of preterm labor management: inpatient versus outpatient,” Journal of Perinatology, vol. 24, no. 8, pp. 515–519, 2004.
  36. J. P. Elliott, N. Istwan, D. Jacques, et al., “Expectant management of the quadruplet pregnancy: inpatient or outpatient?” American Journal of Obstetrics and Gynecology, vol. 185, article 110, 2001.
  37. J. P. Elliott, N. K. Bergauer, D. L. Jacques, S. K. Coleman, and G. J. Stanziano, “Pregnancy prolongation in triplet pregnancies: oral versus continuous subcutaneous terbutaline,” Journal of Reproductive Medicine, vol. 46, no. 11, pp. 975–982, 2001.
  38. F. Lam, N. K. Bergauer, D. Jacques, S. K. Coleman, and G. J. Stanziano, “Clinical and cost effectiveness of continuous subcutaneous terbutaline versus oral tocolytics for treatment of recurrent preterm labor in twin gestations,” Journal of Perinatology, vol. 21, no. 7, pp. 444–450, 2001.
  39. J. P. Elliott, N. B. Istwan, D. Rhea, and G. Stanziano, “The occurrence of adverse events in women receiving continuous subcutaneous terbutaline therapy,” The American Journal of Obstetrics and Gynecology, vol. 191, no. 4, pp. 1277–1282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. L. Hamersley, S. K. Coleman, N. K. Bergauer, L. M. Bartholomew, and T. L. Pinckert, “Delayed-interval delivery in twin pregnancies,” Journal of Reproductive Medicine, vol. 47, no. 2, pp. 125–130, 2002.
  41. R. Viscarello, S. Griffith, and D. Jacques, “The effect of proactive dose acceleration in triplets receiving continuous subcutaneous tocolysis,” Obstetrics and Gynecology, vol. 99, article 12, 2002.
  42. R. Viscarello, S. Griffith, and Charney, “Outpatient management of higher order multiples with a comprehensive careplan improves outcome,” Obstetrics and Gynecology, vol. 99, article 71, 2002.
  43. J. Jones, J. Morrison, N. Istwan, D. Rhea, A. Collins, and G. Stanziano, “The interval to spontaneous delivery following discontinuation of maintenance tocolysis,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 19, no. 6, pp. 331–335, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. J. C. Morrison, S. P. Chauhan, C. S. Carroll Sr., J. A. Bofill, and E. F. Magann, “Continuous subcutaneous terbutaline administration prolongs pregnancy after recurrent preterm labor: a case-control study,” American Journal of Obstetrics and Gynecology, vol. 188, no. 6, pp. 1460–1467, 2003. View at Publisher · View at Google Scholar
  45. F. Lam, N. B. Istwan, D. Jacques, S. K. Coleman, and G. J. Stanziano, “Managing perinatal outcomes: the clinical and cost-effectiveness of pharmacologic treatment of recurrent preterm labor,” Managed Care, vol. 12, no. 7, pp. 39–46, 2003.
  46. A. Roman, A. Rebarber, N. Istwan, D. Rhea, and G. Stanziano, “Clinical and demographic factors associated with spontaneous preterm delivery in twin pregnancies diagnosed with preterm labor at <34 weeks,” American Journal of Obstetrics and Gynecology, vol. 189, no. 6, article S123, 2004.
  47. E. Gaziano, W. Wagner, D. Rhea, N. Istwan, and G. Stanziano, “Inpatients versus outpatient surveillance for singleton pregnancies following inpatient treatment with magnesium sulfate for preterm labor,” in Proceedings of the Society for Gynecologic Investigation Annual Meeting, Houston, Tex, USA, March 2004.
  48. A. Rebarber, A. Roman, and N. Istwan, “Factors associated with spontaneous preterm delivery in singleton gestations,” Obstetrics and Gynecology, vol. 103, no. 4, article 34S, 2004.
  49. A. Fleming, R. Bonebrake, N. Istwan, D. Rhea, S. Coleman, and G. Stanziano, “Pregnancy and economic outcomes in patients treated for recurrent preterm labor,” Journal of Perinatology, vol. 24, no. 4, pp. 223–227, 2004. View at Publisher · View at Google Scholar
  50. E. Gaziano, W. Wagner, and D. Rhea, “Extended hospitalization versus outpatient surveillance in twin gestations following inpatient treatment with magnesium sulfate,” Obstetrics and Gynecology, vol. 103, article 34S, 2004.
  51. H. Brown and G. Stanziano, “Differences in pregnancy outcome in Medicaid versus commercially insured patients with preterm labor,” Obstetrics and Gynecology, vol. 105, no. 4, pp. 74S–75S, 2005.
  52. R. B. Newman, N. B. Istwan, D. Rhea, and G. Stanziano, “Medicaid compared with commercially insured twin pregnancies,” Obstetrics and Gynecology, vol. 107, no. 4, p. 34S, 2006.
  53. D. McWeeney, R. Miller, D. Rhea, and G. Stanziano, “Probability of prematurity by cervical dilatation and gestational age at preterm labor,” Obstetrics and Gynecology, vol. 107, no. 4, p. 31S, 2006.
  54. A. Rebarber, J. Cleary-Goldman, N. Istwan, D. Rhea, G. Stanziano, and D. Saltzman, “The association of elective cessation of tocolysis and preterm birth in singleton gestations,” The American Journal of Perinatology, vol. 26, no. 5, pp. 351–355, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. L. de la Torre, N. B. Istwan, C. Desch et al., “Management of recurrent preterm labor in twin gestations with nifedipine tocolysis,” The American Journal of Perinatology, vol. 25, no. 9, pp. 555–560, 2008. View at Publisher · View at Google Scholar
  56. A. A. Flick, L. de la Torre, L. E. Roca et al., “An examination of the clinical benefits and cost-effectiveness of tocolytic replacement following recurrent preterm labor,” The American Journal of Perinatology, vol. 27, no. 1, pp. 53–59, 2010. View at Publisher · View at Google Scholar
  57. R. K. Creasy, M. S. Golbus, and R. K. Laros, “Oral ritodrine maintenance in the treatment of preterm labor,” The American Journal of Obstetrics and Gynecology, vol. 137, no. 2, pp. 212–219, 1980. View at Scopus
  58. R. Lewis, B. M. Mercer, M. Salama, M. A. Walsh, and B. M. Sibai, “Oral terbutaline after parenteral tocolysis: a randomized, double- blind, placebo-controlled trial,” The American Journal of Obstetrics and Gynecology, vol. 175, no. 4, pp. 834–837, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. G. A. Macones, M. Berlin, and J. A. Berlin, “Efficacy of oral beta-antagonist maintenance therapy in preterm labor: a meta-analysis,” Obstetrics and Gynecology, vol. 85, no. 2, pp. 313–317, 1995. View at Publisher · View at Google Scholar · View at Scopus
  60. B. V. Parilla, S. L. Dooley, J. P. Minogue, and M. L. Socol, “The efficacy of oral terbutaline after intravenous tocolysis,” The American Journal of Obstetrics and Gynecology, vol. 169, no. 4, pp. 965–969, 1993. View at Scopus
  61. S. M. Brown and N. A. Tejani, “Terbutaline sulfate in the prevention of recurrence of premature labor,” Obstetrics and Gynecology, vol. 57, no. 1, pp. 22–25, 1981. View at Scopus
  62. S. N. Caritis, G. Toig, L. A. Heddinger, and G. Ashmead, “A double-blind study comparing ritodrine and terbutaline in the treatment of preterm labor,” The American Journal of Obstetrics and Gynecology, vol. 150, no. 1, pp. 7–14, 1984. View at Scopus
  63. G. Berg, C. Lindberg, and G. Ryden, “Terbutaline in the treatment of preterm labour,” European Journal of Respiratory Diseases, vol. 65, no. 134, pp. 219–230, 1984. View at Scopus
  64. C. P. Plummer, “Evaluation of maternal and neonatal outcomes after maintenance tocolysis: a retrospective study,” Journal of Obstetics and Gynaecology Research, vol. 38, no. 1, pp. 198–202, 2012. View at Publisher · View at Google Scholar
  65. R. W. Martin, J. N. Martin, J. A. Pryor, D. K. Gaddy, W. L. Wiser, and J. C. Morrison, “Comparison of oral ritodrine and magnesium gluconate for ambulatory tocolysis,” The American Journal of Obstetrics and Gynecology, vol. 158, no. 6, pp. 1440–1445, 1988. View at Scopus
  66. R. W. Martin, K. G. Perry, W. Hess, J. N. Martin, and J. C. Morrison, “Oral magnesium and the prevention of preterm labor in a high-risk group of patients,” The American Journal of Obstetrics and Gynecology, vol. 166, no. 1, pp. 144–147, 1992. View at Scopus
  67. S. Rodts-Palenik and J. C. Morrison, “Tocolysis: an update for the practitioner,” Obstetrical and Gynecological Survey, vol. 57, no. 5, supplement 2, pp. S9–S34, 2002. View at Scopus
  68. Y. Y. El-Sayed, R. H. Holbrook Jr., R. Gibson, U. Chitkara, M. L. Druzin, and D. Baba, “Diltiazem for maintenance tocolysis of preterm labor: comparison to nifedipine in a randomized trial,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 7, no. 5, pp. 217–221, 1998. View at Scopus
  69. D. B. Carr, A. L. Clark, K. Kernek, and J. A. Spinnato, “Maintenance oral nifedipine for preterm labor: a randomized clinical trial,” The American Journal of Obstetrics and Gynecology, vol. 181, no. 4, pp. 822–827, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. A. J. van Veen, M. J. Pelinck, M. G. van Pampus, and J. J. H. M. Erwich, “Severe hypotension and fetal death due to tocolysis with nifedipine,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 112, no. 4, pp. 509–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. D. N. M. Papatsonis, B. Carbonne, G. A. Dekker, V. Flenady, and J. F. King, “Severe hypotension and fetal death due to tocolysis with nifedipine,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 112, no. 11, pp. 1582–1583, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Bal, S. Thierry, E. Brocas, M. Adam, A. van de Louw, and A. Tenaillon, “Pulmonary edema induced by calcium-channel blockade for tocolysis,” Anesthesia and Analgesia, vol. 99, no. 3, pp. 910–911, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. S. L. Koontz, S. A. Friedman, and M. L. Schwartz, “Symptomatic hypocalcemia after tocolytic therapy with magnesium sulfate and nifedipine,” The American Journal of Obstetrics and Gynecology, vol. 190, no. 6, pp. 1773–1776, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. C. K. Klauser, C. M. Briery, S. I. Kizar, R. M. Martin, M. A. Kosek, and J. C. Morrison, “Effect of antenatal tocolysis on neonate outcome,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 25, no. 12, pp. 2778–2781, 2012. View at Publisher · View at Google Scholar
  75. N. B. Meirowitz, C. V. Ananth, J. C. Smulian, and A. M. Vintzileos, “Value of maintenance therapy with oral tocolytics: a systematic review,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 8, no. 4, pp. 177–183, 1999. View at Scopus
  76. Cochrane Abstract, “Oxytocin receptor antagonists for inhibiting preterm labour,” Obstetrics and Gynecology, vol. 110, no. 1, pp. 180–181, 2007. View at Publisher · View at Google Scholar
  77. P. Husslein, L. C. Roura, J. W. Dudenhausen et al., “Atosiban versus usual care for the management of preterm labor,” Journal of Perinatal Medicine, vol. 35, no. 4, pp. 305–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. J. C. Morrison, J. R. Allbert, R. C. Floyd, C. S. Bale, C. H. Lou, and K. S. Gookin, “Interval to delivery in high-risk patients: do tocolytic agents really work?” International Journal of Gynecology and Obstetrics, vol. 38, no. 3, pp. 189–193, 1992. View at Publisher · View at Google Scholar · View at Scopus
  79. T. A. Slotkin, J. T. Auman, and F. J. Seidler, “Ontogenesis of β-adrenoceptor signaling: implications for perinatal physiology and for fetal effects of tocolytic drugs,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 1, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Y. Owens, K. L. Wallace, N. Mamoon, J. Wyatt-Ashmead, and W. A. Bennett, “Absence of neurotoxicity with medicinal grade terbutaline in the rat model,” Reproductive Toxicology, vol. 31, no. 4, pp. 447–453, 2011. View at Publisher · View at Google Scholar
  81. M. C. Rhodes, F. J. Seidler, A. Abdel-Rahman et al., “Terbutaline is a developmental neurotoxicant: effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 529–537, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Meyer, F. J. Seidler, J. E. Aldridge, and T. A. Slotkin, “Developmental exposure to terbutaline alters cell signaling in mature rat brain regions and augments the effects of subsequent neonatal exposure to the organophosphorus insecticide chlorpyrifos,” Toxicology and Applied Pharmacology, vol. 203, no. 2, pp. 154–166, 2005. View at Publisher · View at Google Scholar · View at Scopus